What to watch for six months after office care

What to record before changing care

Pick one task before treatment. Use that same task later so you aren't relying on memory.

Note your sleep, swelling and walking distance. Your notes don't need a form or a daily report.

Keep the check easy to repeat. Use the same task after treatment, because switching from a normal walk to an easier task can make the result look better than your daily life feels on most days.

When to discuss an office treatment

Have the joint examined when the ache blocks sleep or normal work. Bring notes on the sore motions and treatments you've tried before.

The clinic calls these non-surgical office options biologic therapies; one is concentrated PRP taken from your blood. The letters in PRP stand for platelet-rich plasma, and staff prepare it by spinning your blood and collecting its platelet-rich part for the sore joint.

Concentrated means the platelet-rich part has been gathered. Ask for the title and training of the medical provider who'll examine you and give the care.

The catch is simple. Nobody can promise a set result or say exactly how long relief will last.

What to track after the visit

Check the task you chose before treatment. Also record sleep, swelling and any unwanted soreness.

Keep your activity fairly steady while comparing weeks. Extra rest can make a treatment seem better than it was.

Look for useful change, not one good afternoon. Your notes will help the clinic decide what happens next.

When to call before six months

Call when soreness keeps rising. You don't need to wait for the next booked check.

Fever, spreading redness or sudden weakness needs faster care. A regular follow-up isn't meant for urgent warning signs.

If improvement stops, ask what the clinic would change. Don't keep paying only because another month has passed.

Sources

1. A meta-analysis of 14 placebo cohorts across 13 Level I trials in 1,076 knee osteoarthritis patients found that intra-articular saline - the placebo - produced pain and function improvements exceeding the minimal clinically important difference at 3 and 6 months.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. Am J Sports Med, 2017. DOI: 10.1177/0363546516680607.

2. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

3. A network meta-analysis of 79 randomized trials in 8,761 patients ranked the intra-articular injectables for knee osteoarthritis on VAS and WOMAC at 1, 3, 6 and 12 months, placing the cell-based options within a crowded field rather than above it.

   Anil U, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

4. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.